GlassScriptPhysician profile
Lucas M Heller
NPI 1982970976
$198,889.20
in general payments reported to CMS, 2019-2025
36 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,062 · 2020: $17K · 2021: $51K · 2022: $56K · 2023: $17K · 2024: $20K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $4,623 · Food and Beverage: $3,374 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,054.44 |
| Travel and Lodging | $4,623.33 |
| Food and Beverage | $3,374.23 |
| Education | $181.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $179,408.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,353.25 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $6,852.01 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $675.93 | 2019-2024 | Farxiga |
| Amgen INC. | $346.26 | 2019-2025 | Repatha, Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $192.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $191.72 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $186.55 | 2019-2024 | Unithroid |
| Dexcom, INC. | $135.73 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $132.31 | 2019-2025 | |
| Insulet Corporation | $123.19 | 2019-2025 | Omnipod |
| Cequr Corporation | $117.71 | 2025 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $112.99 | 2019 | |
| Medtronic Minimed, INC. | $99.85 | 2019-2020 | |
| Astellas Pharma US INC | $98.60 | 2024 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $91.25 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Tandem Diabetes Care, INC. | $86.66 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $70.32 | 2019-2021 | |
| Beta Bionics, INC. | $69.82 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Shire North American Group INC | $68.41 | 2019 | |
| Medtronic, INC. | $51.34 | 2021-2025 | Minimed 780g |
| Amarin Pharma, INC. | $49.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $49.53 | 2021-2025 | Gvoke Hypopen |
| Cumberland Pharmaceuticals, INC. | $46.58 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.70 | 2021-2022 | |
| Clarus Therapeutics INC. | $35.07 | 2021 | |
| Verity Pharmaceuticals INC. | $34.07 | 2024-2025 | Tlando |
| Antares Pharma, INC. | $31.66 | 2021-2023 | Tlando, Nocdurna, Xyosted |
| Averitas Pharma INC. | $27.55 | 2025 | Qutenza |
| Corcept Therapeutics | $19.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.39 | 2025 | Strensiq |
| Horizon Therapeutics Plc | $18.35 | 2020 | |
| Neurocrine Biosciences, INC. | $13.76 | 2025 | |
| Radius Health, INC. | $13.24 | 2019 | |
| Becton, Dickinson and Company | $12.30 | 2019 | |
| Lifescan, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucas Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.